Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $29.99 in the last session, down -5.78% from day before closing price of $31.83. In other words, the price has decreased by -$5.78 from its previous closing price. On the day, 1.77 million shares were traded.
Ratios:
We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 59.21 and its Current Ratio is at 59.21. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when ANDREW MEYER bought 3,334 shares for $32.89 per share.
Meyer Andrew Hollman sold 3,334 shares of JANX for $140,999 on Feb 03 ’25. The Chief Business Officer now owns 82,139 shares after completing the transaction at $42.29 per share. On Feb 03 ’25, another insider, ANDREW MEYER, who serves as the Officer of the company, bought 3,334 shares for $43.48 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 167.38 while its Price-to-Book (P/B) ratio in mrq is 1.73.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $31.36. The 50-Day Moving Average of the stock is -31.22%, while the 200-Day Moving Average is calculated to be -35.08%.
Shares Statistics:
A total of 59.06M shares are outstanding, with a floating share count of 49.18M. Insiders hold about 16.79% of the company’s shares, while institutions hold 106.49% stake in the company.
Earnings Estimates
A comprehensive evaluation of Janux Therapeutics Inc (JANX) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.31 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.29 and -$3.32 for the fiscal current year, implying an average EPS of -$2.04. EPS for the following year is -$2.68, with 8.0 analysts recommending between -$1.55 and -$4.84.
